Management of intracranial bleeding associated with dabigatran use in a neuroscience hospital by Perez, MD, Alejandro et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Pharmacology and Experimental
Therapeutics Faculty Papers
Department of Pharmacology and Experimental
Therapeutics
6-13-2013
Management of intracranial bleeding associated
with dabigatran use in a neuroscience hospital
Alejandro Perez, MD
Thomas Jefferson University Hospital, Alejandro.Perez@jefferson.edu
Lynda Thomson
Thomas Jefferson University, Lynda.Thomson@jefferson.edu
Geno J. Merli, MD
Thomas Jefferson University Hospital, Geno.Merli@jefferson.edu
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/petfp
Part of the Medical Specialties Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Pharmacology and Experimental Therapeutics Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For
more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Perez, MD, Alejandro; Thomson, Lynda; and Merli, MD, Geno J., "Management of intracranial
bleeding associated with dabigatran use in a neuroscience hospital" (2013). Department of
Pharmacology and Experimental Therapeutics Faculty Papers. Paper 43.
http://jdc.jefferson.edu/petfp/43
Management of intracranial bleeding associated with dabigatran use in a neuroscience hospital 
Alejandro Perez, MD; Lynda Thomson, Pharm D;  Geno J Merli, MD 
Jefferson Vascular Center, Thomas Jefferson University Hospital 
ABSTRACT SUMMARY 
 Vitamin K antagonists (VKAs), such as 
warfarin, have been the mainstay of 
therapy for long-term  anticoagulation 
management of AF for over 60 years. 
Unfortunately, VKAs have: 
 a slow onset of therapeutic effect 
 a narrow therapeutic index 
 numerous dietary and drug interactions 
 a variable anticoagulation response  
 a requirement for frequent 
anticoagulation monitoring 
  This prompted the development of novel 
oral anticoagulants which directly target 
crucial steps in the coagulation cascade, 
either Factor Xa or thrombin (Factor IIa).  
Dabigatran  etexilate, hereafter referred to 
as dabigatran, is an oral direct thrombin 
inhibitor, and the first of the novel 
anticoagulants to gain widespread use in 
the U.S. for anticoagulation in the setting of 
non-valvular  AF.  
 There is no currently available reversal 
agent for dabigatran, although it is 
dialyzable.  Because of the predominant 
renal elimination, kidney dysfunction can 
also predispose to potential bleeding 
complications.  As the use of dabigatran 
began to increase in the community, an 
initial surveillance of associated bleeding 
episodes in a neuroscience hospital was 
characterized. 
BACKGROUND 
RESULTS 
DISCUSSION 
These data highlight the difficulty with 
monitoring effect of anticoagulation with 
traditional anticoagulation monitoring 
techniques.  Although a presumed benefit of 
the novel anticoagulants is not needing to be 
monitored, there are instances where effect 
may need to be quantified.  Additionally, the 
adverse events noted were in the elderly and 
those with compromised renal function.  
 
We assert the necessity of needing an 
anticoagulation stewardship program that 
prepares institutions for the introduction of 
novel anticoagulants.  Essential elements for 
this type of program include: 
 
• Education of appropriate dosing and indications. 
• Plan for management of adverse events including 
mobilization of dialysis team with involvement of 
nephrology and vascular/hematology specialists. 
• Continuous monitoring for adverse events to target 
areas of prevention. 
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DISCLOSURES 
Geno J. Merli:  
 Grant/Research Support    
  BMS, Bayer, Sanofi-aventis 
  
 Scientific Consultant    
   BMS, Bayer, Sanofi-aventis 
 
All other Authors: No disclosures 
 
 5 cases of intracranial bleeding associated 
with dabigatran occurred from 12/2011-
4/12. All patients were on anticoagulation 
for AF, the most commonly prescribed dose 
of dabigatran was 150 mg BID.  
Background: Dabigatran, an alternative to warfarin for prevention of stroke 
with non-valvular atrial fibrillation (AF), offers advantages of a fixed dosage, 
minimal laboratory monitoring and limited medication interactions. 
Dabigatran requires dosage adjustment in renal dysfunction and is 
contraindicated if severe dysfunction. No identified dabigatran reversal agent 
exists.  
 
Methods: As part of an ongoing quality initiative, novel anticoagulant 
associated adverse events (AE) are monitored at a dedicated neuroscience 
hospital.  
 
Results: 5 cases of intracranial bleeding associated with dabigatran occurred 
from 12/2011-4/2012. All patients were on anticoagulation for AF, the most 
common dose of dabigatran was 150 mg BID. Mean admission values were as 
follows: age 83.2 yrs (range 79-90), serum creatinine 1.48 mg/dL (range 0.9-
3.5), creatinine clearance 45.6 mL/min (18-59) and aPTT 49 seconds (range 32-
60). Strategies for the management of bleeding included withholding 
dabigatran, supportive care, administration of blood products and 
hemodialysis, when required. Dialysis was initiated on 3 patients. One patient 
had 3 dialysis sessions in an effort to normalize coagulation assays and had 
transfusions with 10 units of platelets and 4 units of fresh frozen plasma in an 
effort to stabilize bleeding. One patient died. Mean time for aPTT to normalize 
when abnormal on admission was 30.8 hours (range 21-37).  
 
Conclusions: Appropriate patient selection is required to prevent dabigatran 
associated AE, especially in the setting of advanced age and kidney 
dysfunction. aPTT values may remain prolonged for extended periods, 
despite efforts to normalize. Hospitals need a defined management plan for 
major bleeding associated with novel anticoagulants. 
METHODS 
 An emergency management team including  
the pharmacy, nephrology, hematology 
and/or vascular medicine consult services 
were notified when patients were admitted to 
the hospital for dabigatran - associated 
intracranial bleeding. 
 These patients had their hospital course 
followed for an ongoing quality assessment 
of how to best manage these occurrences  
and help prevent them in the future. 
RESULTS (CONTINUED) 
Case 1: 79 year old male with PMH of paroxysmal AF, HTN, 
CAD, coronary bypass, bioprosthetic aortic valve replacement 
and COPD presented to an outside hospital (OSH) with acute 
onset of right sided weakness and facial droop.  Outpatient 
dabigatran dose had been 75 mg po BID. A CT scan of the 
head showed a left basal ganglia intraparenchymal 
hemorrhage (3 x 2.1cm) with mild edema and no midline shift.  
The patient was transferred to our institution and a repeat CT 
scan of the head showed an irregular left lentiform nucleus 
hemorrhage of 3.7 x 2.5 cm with surrounding edema.  
Admission laboratory values revealed an  aPTT of 54 seconds  
(reference range: 20-38 s), PT 17.5 s  (reference range: 11.2-
14.8 s) and an INR of 1.48. Hemodialysis (HD) was initiated for 
4 hrs (Day 1). Following HD, the aPTT declined to 41 s with a 
repeat assay showing 55 s six hrs later.  A second HD session 
for 3.5 hrs was initiated on Day 2 for worsening mental status 
in the setting of an elevated aPTT. After the second dialysis 
session the aPTT decreased to 40 s.  In an attempt to 
normalize the aPTT, the pt also received rFVIIa (NovosevenR) 
1560 mcg IV x 1 on Day 2. Repeat CT head showed no interval 
change in the hemorrhage and combined MRI/MRA was 
negative for aneurysm.  The aPTT values remained elevated for 
37 hours. 
 
Case 2: 84 year old woman  with a history of AF, HTN, 
hypothyroidism, depression, and cutaneous vasculitis 
presented to an OSH with right  sided weakness, facial droop;  
outpatient  dabigatran dose had been 150 mg po BID. Head CT: 
1.7 x 2.4 cm hyperdensity in left thalamus.  On admission, 
aPTT was 60 s, PT was 18.1 s and INR was 1.54.   aPTT was 
elevated for 37 hours.  No dialysis was initiated. 
 
Case 3: 80 year old woman with a PMH of HTN, AF, and CAD 
presented following a fall at home to an outside emergency 
department. On arrival a CT scan of the head showed a 
subarachnoid hemorrhage (SAH).  Dabigatran dose had been 
150 mg po BID. On transfer to our facility, a repeat CT scan of 
the head showed interval development of a large SAH within 
the suprasellar cistern, right perimesencepahlic cistern, and 
the left prepontine cistern. On admission, aPTT  was  60 s, PT 
was 16.8 s, and INR = 1.4. She had 3 sessions of hemodialysis 
during days 1 and 2 of  hospitalization. Received 4 units FFP 
and 10 units platelets. Repeat imaging showed no interval 
change in the hemorrhage.  The aPTT value after 2 sessions of 
HD was 36 s; aPTT remained elevated for 28 hours. 
• Appropriate patient selection is required 
to prevent dabigatran associated AE 
• Advanced age and kidney dysfunction 
are high risk groups for AE.  
• aPTT values may remain prolonged for 
extended periods.  
• Hospitals need a defined management 
plan for AE and major bleeding 
associated with novel anticoagulants 
 
Case 4: 83 year old man with PMH of AF, cardiomyopathy, 
(ejection fraction 15%), AICD with pacemaker, COPD and 
severe aortic stenosis ,with a valve area of 0.8 cm2 was 
admitted with  a subdural hemorrhage and cardiogenic 
shock.  He developed progressive multi-organ failure. On 
admission, aPTT 32 s, PT 15.9 s, and INR 1.3.  The patient 
expired during the hospitalization.  Dabigatran dose was 
unknown. No dialysis was initiated. 
 
Case 5: 90 old female with a  history of HTN, CAD, AF, and 
both a hip and knee replacement was found on the floor 
after a fall and was transferred from an OSH. Initial 
laboratory evaluation demonstrated a PT of 22.3 sec, 
corresponding INR of 2.1, and an aPTT of 65.2 s.  CT scan 
of the head demonstrated a left temporo-pariatal acute 
subdural hemorrhage (SDH) measuring 7 mm, a SAH in 
the sylvian fissure and supracellar cistern, as well as trace 
intraventricular hemorrhage. On transfer, repeat imaging 
again demonstrated  multicompartmental hemorrhage, 
with evolution. Initial aPTT value was 39 s, PT was 21.8 s, 
with  INR of 1.97. Following a session of high flux 
hemodialysis for 4 hours the  aPTT was  41 s. The patient 
dislodged her own hemodialysis catheter , however,  
remained clinically stable with no interval changes on the 
repeat imaging.  Accordingly, no further intervention was 
required.  The aPTT values remained  elevated for 27 
hours. 
aPTT values for 5 patients according to time collection 
Days in ICU       , Total Length of Stay (Days)  
